Clark Richard V, Walker Ann C, O'Connor-Semmes Robin L, Leonard Michael S, Miller Ram R, Stimpson Stephen A, Turner Scott M, Ravussin Eric, Cefalu William T, Hellerstein Marc K, Evans William J
Muscle Metabolism Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline R&D, Research Triangle Park, North Carolina;
KineMed Inc., Emeryville, California;
J Appl Physiol (1985). 2014 Jun 15;116(12):1605-13. doi: 10.1152/japplphysiol.00045.2014. Epub 2014 Apr 24.
Current methods for clinical estimation of total body skeletal muscle mass have significant limitations. We tested the hypothesis that creatine (methyl-d3) dilution (D3-creatine) measured by enrichment of urine D3-creatinine reveals total body creatine pool size, providing an accurate estimate of total body skeletal muscle mass. Healthy subjects with different muscle masses [n = 35: 20 men (19-30 yr, 70-84 yr), 15 postmenopausal women (51-62 yr, 70-84 yr)] were housed for 5 days. Optimal tracer dose was explored with single oral doses of 30, 60, or 100 mg D3-creatine given on day 1. Serial plasma samples were collected for D3-creatine pharmacokinetics. All urine was collected through day 5. Creatine and creatinine (deuterated and unlabeled) were measured by liquid chromatography mass spectrometry. Total body creatine pool size and muscle mass were calculated from D3-creatinine enrichment in urine. Muscle mass was also measured by magnetic resonance imaging (MRI), dual-energy x-ray absorptiometry (DXA), and traditional 24-h urine creatinine. D3-creatine was rapidly absorbed and cleared with variable urinary excretion. Isotopic steady-state of D3-creatinine enrichment in the urine was achieved by 30.7 ± 11.2 h. Mean steady-state enrichment in urine provided muscle mass estimates that correlated well with MRI estimates for all subjects (r = 0.868, P < 0.0001), with less bias compared with lean body mass assessment by DXA, which overestimated muscle mass compared with MRI. The dilution of an oral D3-creatine dose determined by urine D3-creatinine enrichment provides an estimate of total body muscle mass strongly correlated with estimates from serial MRI with less bias than total lean body mass assessment by DXA.
目前临床评估全身骨骼肌质量的方法存在显著局限性。我们检验了这样一个假设:通过尿液中D3-肌酐的富集来测量的肌酸(甲基-d3)稀释(D3-肌酸)能够揭示全身肌酸池大小,从而准确估计全身骨骼肌质量。对具有不同肌肉质量的健康受试者[n = 35:20名男性(19 - 30岁,70 - 84岁),15名绝经后女性(51 - 62岁,70 - 84岁)]进行了为期5天的观察。在第1天给予单次口服30、60或100毫克D3-肌酸的剂量,探索最佳示踪剂剂量。采集系列血浆样本用于D3-肌酸的药代动力学研究。在第5天前收集所有尿液。通过液相色谱质谱法测量肌酸和肌酐(氘代和未标记的)。根据尿液中D3-肌酐的富集情况计算全身肌酸池大小和肌肉质量。还通过磁共振成像(MRI)、双能X线吸收法(DXA)和传统的24小时尿肌酐测量肌肉质量。D3-肌酸吸收迅速,清除过程中尿排泄量可变。尿液中D3-肌酐富集的同位素稳态在30.7 ± 11.2小时达到。尿液中的平均稳态富集提供的肌肉质量估计值与所有受试者的MRI估计值相关性良好(r = 0.868,P < 0.0001),与DXA评估瘦体重相比偏差较小,DXA评估的肌肉质量相对于MRI高估了。通过尿液D3-肌酐富集确定的口服D3-肌酸剂量的稀释情况可提供全身肌肉质量的估计值,与系列MRI的估计值高度相关,且偏差小于DXA评估的总瘦体重。